A study published today could revolutionize Alzheimer’s therapy. Researchers at Baylor College of Medicine have discovered that astrocytes – previously underestimated support cells – can break down toxic plaques. The key: a genetic switch called Sox9.
The results in Nature Neuroscience show: If you activate this molecular lever, the star-shaped cells transform into highly efficient cleaning machines. They literally devour beta-amyloid deposits – exactly the protein clumps that are considered the main feature of Alzheimer’s. Where current antibody therapies often only have a limited effect, the body’s own clean-up commands could shape the treatment of the next decade.
For decades, research revolved around neurons and external antibodies. The new study suggests a radically different path: mobilizing internal defenses.
The team identified the transcription factor Sox9 as a crucial regulator. In Alzheimer’s mouse models, artificially increasing Sox9 production triggered a remarkable chain reaction. The astrocytes suddenly began to actively surround and eliminate the toxic deposits.
Advertisement
In keeping with the topic of memory and dementia: Our free PDF report “Brain training made easy” shows 7 secrets, 11 exercises suitable for everyday use and a practical self-test with which you can specifically strengthen concentration and memory. Many exercises only take 2-5 minutes and can be immediately integrated into everyday life. Ideal for those affected and their relatives who want to actively reduce the risk of dementia – the results and report come directly by email. Request the free report “Brain training made easy”.
“We found that increasing Sox9 expression stimulated astrocytes to take up more amyloid plaques and remove them from the brain like a vacuum cleaner,” explains study leader Dr. Deneen. The cells normally lose this ability as the brain ages – or do not even show it to this extent.
MEGF10: The molecular hands of astrocytes
Table of Contents
But how do the cells “know” which plaques to attack? The study also provides a precise answer for this – crucial for drug development.
Sox9 upregulates a specific phagocytosis receptor: MEGF10. These molecular “hands” allow astrocytes to grasp toxic proteins. Without Sox9, MEGF10 remains at low levels and the plaques remain untouched. With Sox9, the receptor covers the cell surface and dramatically increases feeding activity.
The results went beyond just plaque reduction. Mice with activated astrocytes showed less memory loss and more intact synaptic communication than control groups. Cleansing apparently actually stops the neurodegenerative process.
Paradigm shift: astrocytes outperform microglia
Until recently, microglia – the resident immune cells – were almost exclusively considered the primary candidates for plaque clearance. In late 2024, a study from Weill Cornell Medicine showed that these cells can break down debris through “digestive exophagy.”
But microglia have dark sides:
- They release inflammatory messenger substances under stress
- They can cause additional damage to brain tissue
- When overloaded, they even contribute to the spread of plaque material
Today’s findings position astrocytes as a safer alternative. In contrast to often “aggressive” microglia, Sox9-activated cells do their work without triggering harmful neuroinflammatory cascades. “Strengthening the natural cleaning ability of astrocytes could be just as important as preventing plaque formation,” say the researchers.
The puzzle is completed: Glymphatic system meets astrocytes
The discovery perfectly complements the growing understanding of brain waste disposal. It wasn’t until October 2024 that researchers at Oregon Health & Science University demonstrated this glymphatic system in the living human brain – a network of channels that transports cerebrospinal fluid along the blood vessels.
The interaction:
- Astrocytes: Local “street sweepers” who shred garbage on site
- Glymphatic system: The “sewerage system” for the removal of dissolved waste materials
Dysfunction of both systems in old age seems to be the perfect storm for Alzheimer’s. With Sox9 we now know a molecular lever for the cellular component. Biotech analysts see enormous potential for gene therapies or “small molecule” drugs that modulate Sox9 in glial cells – without directly manipulating sensitive neurons.
Experts react enthusiastically
The scientific community is enthusiastic. The approach could circumvent the problem of “antibody clearance.” Current drugs such as lecanemab mark plaques for immune defense, but often lead to side effects such as brain swelling. An internal mechanism via astrocytes might be more tolerable.
“This is proof of a principle that we have been looking for for years,” comments a neurologist at the Charité Berlin. “If astrocytes resume the protective role they play in early life, we could actively remediate the cellular environment – not just slow disease progression.”
The path to the patient: What comes next?
The results are based on mouse models. The next step: check whether human astrocytes show the same Sox9-MEGF10 mechanism and whether it can be reactivated pharmacologically.
Expected developments in the next 12-24 months:
- Validation studies: Sox9 expression in human brain tissue from Alzheimer’s patients
- Active ingredient screening: Search for molecules that specifically upregulate Sox9 in astrocytes
- Combination therapies: Astrocyte activation combined with existing anti-amyloid therapies
Could November 21, 2025 go down in history as the day we realized: The solution to Alzheimer’s was already dormant in our heads – waiting for the right signal to wake up?
Advertisement
By the way: A short self-test reveals in about 2 minutes whether your forgetfulness is still normal or whether a closer look would make sense. The free guide “Brain training made easy” also provides simple exercises, nutritional tips and an anonymous self-test, which you will receive by email. Get practical tools now that you can use to strengthen concentration and memory in everyday life. Get your memory exercises & self-test now
